RLMD - Relmada Therapeutics tumbles 37% post market on late-stage depression drug data
- For the second time, a phase 3 trial of Relmada Therapeutics' ( NASDAQ: RLMD ) depression candidate REL-1017 has failed .
- Shares are down 37% in after-hours trading.
- Top-line results from the RELIANCE I study showed the candidate missed its primary endpoint, statistically significant improvement in depression symptoms compared to placebo acoording to the Montgomery-Asberg Depression Rating Scale (MADRS).
- REL-1017 is under investigation as an adjunct to standard antidepressants.
- As in the RELIANCE III trial that reported in October, there were two study sites where the placebo significantly outperformed the treatment arm.
For further details see:
Relmada Therapeutics tumbles 37% post market on late-stage depression drug data